Infliximab for the treatment of recalcitrant bullous Sweet syndrome in a 10‐year‐old girl

We report the case of a 10‐year‐old girl with bullous Sweet syndrome, recalcitrant to high‐dose systemic corticosteroids. Subsequent treatment with infliximab resulted in a rapid improvement in cutaneous lesions and systemic symptoms. Cutis laxa was noted in the healed skin. We propose early second‐...

Full description

Saved in:

Bibliographic Details
Published in:	Pediatric dermatology Vol. 37; no. 6; pp. 1183 - 1184
Main Authors:	Knöpfel, Nicole, Theiler, Martin, Luchsinger, Isabelle, Hafner, Bettina, Brunner, Corinne, Kolm, Isabel, Weibel, Lisa
Format:	Journal Article
Language:	English
Published:	United States Wiley Subscription Services, Inc 01-11-2020
Subjects:	acute febrile neutrophilic dermatosis bullous Sweet syndrome cardiovascular elastolysis Case reports Child Corticosteroids Cutis Laxa Dermatology Female Humans Immunotherapy Infliximab Infliximab - therapeutic use Monoclonal antibodies Pediatrics postinflammatory cutis laxa Skin Skin diseases Sweet Syndrome - diagnosis Sweet Syndrome - drug therapy Sweet's syndrome TNF inhibitors Tumor necrosis factor-α cardiovascular elastolysis bullous Sweet syndrome acute febrile neutrophilic dermatosis postinflammatory cutis laxa
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	We report the case of a 10‐year‐old girl with bullous Sweet syndrome, recalcitrant to high‐dose systemic corticosteroids. Subsequent treatment with infliximab resulted in a rapid improvement in cutaneous lesions and systemic symptoms. Cutis laxa was noted in the healed skin. We propose early second‐line treatment with infliximab in children with steroid‐refractory Sweet syndrome.
Bibliography:	ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3
ISSN:	0736-8046 1525-1470
DOI:	10.1111/pde.14356